{"title":"释放抗生素的可生物降解复合骨水泥治疗实验性慢性颌面骨感染的研究。","authors":"Surajit Mistry, Subhasis Roy, Debarati Bhowmick, Shuvojit Mistry, Jui Chakraborty, Rajiv Roy, Indrasri Das","doi":"10.1002/jbm.a.37858","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Chronic osteomyelitis of the maxillofacial bones (i.e., jaw bones) is a persistent infection that requires effective treatment. Because systemic antibiotics seldom reach necrotic areas to remove bone infection, local antibiotic carriers such as antibiotic-loaded bone cement can be tried. It is critical to assess the biosafety and efficacy of two new antibiotic-loaded biodegradable composite bone cements for treating chronic mandibular osteomyelitis, and their drug eluting efficiency and other relevant aspects prior to clinical trial. The physico-mechanical properties, and drug release capacity of the cements were determined to be suitable for in vivo application. After inducing chronic osteomyelitis with Staphylococcal strains in 30 female rabbit mandibles, bioactive glass composite cement (0.5 g) and biphasic calcium phosphate composite cement (0.5 g) were implanted in 18 defects (nine/test group) for 84 days to compare the therapeutic efficacy with traditional therapy (control, debridement plus antibiotics in nine defects) using microscopic, micrographic, and radiological examination. Antibiotic concentrations in bone (vancomycin: 34.7–53.2 μg/g, tobramycin: 2.1–2.87 μg/g) after 21 days of installation for both cements were sufficient to eradicate pathogens without causing adverse events. In vivo tests suggest that cement groups outperformed (<i>p</i> < 0.05) traditional therapy in terms of infection clearance and osteoconduction. The gross histologic and micrographic scores of biphasic calcium phosphate composite cement (10.33 ± 0.58 and 8.33 ± 1.53, respectively) indicated that the cement barely surpassed (<i>p</i> > 0.05) the other composite cement (12.67 ± 1.53 and 10.0 ± 1.0, respectively). These findings emphasize the potential of antibiotic loaded composite cements as an effective treatment option for chronic maxillofacial osteomyelitis, offering a safer and more efficient alternative to traditional therapy.</p>\n </div>","PeriodicalId":15142,"journal":{"name":"Journal of biomedical materials research. Part A","volume":"113 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigation of Antibiotic-Releasing Biodegradable Composite Bone Cements for Treating Experimental Chronic Maxillofacial Bone Infection\",\"authors\":\"Surajit Mistry, Subhasis Roy, Debarati Bhowmick, Shuvojit Mistry, Jui Chakraborty, Rajiv Roy, Indrasri Das\",\"doi\":\"10.1002/jbm.a.37858\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Chronic osteomyelitis of the maxillofacial bones (i.e., jaw bones) is a persistent infection that requires effective treatment. Because systemic antibiotics seldom reach necrotic areas to remove bone infection, local antibiotic carriers such as antibiotic-loaded bone cement can be tried. It is critical to assess the biosafety and efficacy of two new antibiotic-loaded biodegradable composite bone cements for treating chronic mandibular osteomyelitis, and their drug eluting efficiency and other relevant aspects prior to clinical trial. The physico-mechanical properties, and drug release capacity of the cements were determined to be suitable for in vivo application. After inducing chronic osteomyelitis with Staphylococcal strains in 30 female rabbit mandibles, bioactive glass composite cement (0.5 g) and biphasic calcium phosphate composite cement (0.5 g) were implanted in 18 defects (nine/test group) for 84 days to compare the therapeutic efficacy with traditional therapy (control, debridement plus antibiotics in nine defects) using microscopic, micrographic, and radiological examination. Antibiotic concentrations in bone (vancomycin: 34.7–53.2 μg/g, tobramycin: 2.1–2.87 μg/g) after 21 days of installation for both cements were sufficient to eradicate pathogens without causing adverse events. In vivo tests suggest that cement groups outperformed (<i>p</i> < 0.05) traditional therapy in terms of infection clearance and osteoconduction. The gross histologic and micrographic scores of biphasic calcium phosphate composite cement (10.33 ± 0.58 and 8.33 ± 1.53, respectively) indicated that the cement barely surpassed (<i>p</i> > 0.05) the other composite cement (12.67 ± 1.53 and 10.0 ± 1.0, respectively). These findings emphasize the potential of antibiotic loaded composite cements as an effective treatment option for chronic maxillofacial osteomyelitis, offering a safer and more efficient alternative to traditional therapy.</p>\\n </div>\",\"PeriodicalId\":15142,\"journal\":{\"name\":\"Journal of biomedical materials research. Part A\",\"volume\":\"113 1\",\"pages\":\"\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-12-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biomedical materials research. Part A\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jbm.a.37858\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical materials research. Part A","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jbm.a.37858","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Investigation of Antibiotic-Releasing Biodegradable Composite Bone Cements for Treating Experimental Chronic Maxillofacial Bone Infection
Chronic osteomyelitis of the maxillofacial bones (i.e., jaw bones) is a persistent infection that requires effective treatment. Because systemic antibiotics seldom reach necrotic areas to remove bone infection, local antibiotic carriers such as antibiotic-loaded bone cement can be tried. It is critical to assess the biosafety and efficacy of two new antibiotic-loaded biodegradable composite bone cements for treating chronic mandibular osteomyelitis, and their drug eluting efficiency and other relevant aspects prior to clinical trial. The physico-mechanical properties, and drug release capacity of the cements were determined to be suitable for in vivo application. After inducing chronic osteomyelitis with Staphylococcal strains in 30 female rabbit mandibles, bioactive glass composite cement (0.5 g) and biphasic calcium phosphate composite cement (0.5 g) were implanted in 18 defects (nine/test group) for 84 days to compare the therapeutic efficacy with traditional therapy (control, debridement plus antibiotics in nine defects) using microscopic, micrographic, and radiological examination. Antibiotic concentrations in bone (vancomycin: 34.7–53.2 μg/g, tobramycin: 2.1–2.87 μg/g) after 21 days of installation for both cements were sufficient to eradicate pathogens without causing adverse events. In vivo tests suggest that cement groups outperformed (p < 0.05) traditional therapy in terms of infection clearance and osteoconduction. The gross histologic and micrographic scores of biphasic calcium phosphate composite cement (10.33 ± 0.58 and 8.33 ± 1.53, respectively) indicated that the cement barely surpassed (p > 0.05) the other composite cement (12.67 ± 1.53 and 10.0 ± 1.0, respectively). These findings emphasize the potential of antibiotic loaded composite cements as an effective treatment option for chronic maxillofacial osteomyelitis, offering a safer and more efficient alternative to traditional therapy.
期刊介绍:
The Journal of Biomedical Materials Research Part A is an international, interdisciplinary, English-language publication of original contributions concerning studies of the preparation, performance, and evaluation of biomaterials; the chemical, physical, toxicological, and mechanical behavior of materials in physiological environments; and the response of blood and tissues to biomaterials. The Journal publishes peer-reviewed articles on all relevant biomaterial topics including the science and technology of alloys,polymers, ceramics, and reprocessed animal and human tissues in surgery,dentistry, artificial organs, and other medical devices. The Journal also publishes articles in interdisciplinary areas such as tissue engineering and controlled release technology where biomaterials play a significant role in the performance of the medical device.
The Journal of Biomedical Materials Research is the official journal of the Society for Biomaterials (USA), the Japanese Society for Biomaterials, the Australasian Society for Biomaterials, and the Korean Society for Biomaterials.
Articles are welcomed from all scientists. Membership in the Society for Biomaterials is not a prerequisite for submission.